Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Carrasquer is active.

Publication


Featured researches published by Anna Carrasquer.


Heart | 2017

Outcomes with type 2 myocardial infarction compared with non-ischaemic myocardial injury

Germán Cediel; Maribel González-del-Hoyo; Anna Carrasquer; Rafael Sánchez; Carme Boqué; Alfredo Bardají

Objective To identify patients with type 2 myocardial infarction (MI) and patients with non-ischaemic myocardial injury (NIMI) and to compare their prognosis with those of patients with type 1 MI. Methods A retrospective observational study was performed in 1010 patients admitted to the emergency department of a university hospital with at least one troponin I test between 2012 and 2013. Participants were identified using laboratory records and divided into three groups: type 1 MI (rupture of atheromatous plaque), type 2 MI (imbalance between myocardial oxygen supply and/or demand) and NIMI (patients who did not meet diagnostic criteria for type 1 or type 2 MI). Clinical characteristics and 2-year outcomes were analysed. Results Patients with type 2 MI and NIMI were older, with higher proportion of women and more comorbidities than patients with type 1 MI. Absolute mortality and the adjusted risk for all-cause mortality in both groups were significantly higher than that of patients with type 1 MI (39.7%, HR: 1.41 95% CI 1.02 to 1.94, p=0.038 and 40.0%, HR: 1.54 95% CI 1.16 to 2.04, p=0.002, respectively). Patients with type 2 MI and NIMI tended to present more readmissions due to heart failure (16.5%, HR: 1.55 95% CI 0.87 to 2.76, p=0.133 and 12.3%, HR: 1.15 95% CI 0.70 to 1.90, p=0.580) and less readmission rates due to acute coronary syndrome (ACS) than patients with type 1 MI (2.1%, HR: 0.11 95% CI 0.04 to 0.31, p<0.001 and 4.3%, HR: 0.22 95% CI 0.12 to 0.41, p<0.001), Conclusions Patients diagnosed with type 2 MI and NIMI have higher rates of mortality and lower readmission rates for ACS compared with patients with type 1 MI.


Revista Espanola De Cardiologia | 2015

Troponin Elevation in Patients Without Acute Coronary Syndrome

Alfredo Bardají; Germán Cediel; Anna Carrasquer; Ramón de Castro; Rafael Sánchez; Carmen Boqué

INTRODUCTION AND OBJECTIVES Troponins are specific biomarkers of myocardial injury and are implicated in the diagnosis and prognosis of patients with acute coronary syndrome. Our purpose was to determine the clinical characteristics and prognosis of patients with troponin elevation who are not diagnosed with acute coronary syndrome. METHODS A total of 1032 patients with an emergency room troponin measurement were studied retrospectively, dividing them into 3 groups: 681 patients with no troponin elevation and without acute coronary syndrome, 139 with acute coronary syndrome, and 212 with troponin elevation and not diagnosed with acute coronary syndrome. The clinical characteristics and in-hospital and 12-month mortality of these 3 groups were compared. RESULTS Patients with troponin elevation not diagnosed with acute coronary syndrome were older and had greater comorbidity than patients with acute coronary syndrome or no troponin elevation. The 12-month mortality was 30.2%, compared with 15.1% and 4.7% in the other groups (log rank test, P<.001). In the Cox logistic regression model adjusted for confounding variables, patients with troponin elevation and no diagnosis of acute coronary syndrome had higher mortality compared with patients with negative troponin without acute coronary syndrome (hazard ratio=3.99; 95% confidence interval, 2.36-6.75; P<.001) and similar prognosis as patients with acute coronary syndrome. CONCLUSIONS Troponin elevation is an important predictor of mortality, regardless of the patients final diagnosis.


Revista Espanola De Cardiologia | 2018

Clinical Acceptance of the Universal Definition of Myocardial Infarction

Germán Cediel; Maribel González-del-Hoyo; Gil Bonet; Anna Carrasquer; Carme Boqué; Alfredo Bardají

1. Pérez-Castellanos A, Martı́nez-Sellés M, Mejı́a-Renterı́a H, et al. Tako-tsubo syndrome in men: rare, but with poor prognosis. Rev Esp Cardiol. 2018;71:703–708. 2. Kawaji T, Shiomi H, Morimoto T, et al. Clinical impact of left ventricular outflow tract obstruction in takotsubo cardiomyopathy. Circ J. 2015;79:839–846. 3. Yeh RW, Yu PB, Drachman DE. Takotsubo cardiomyopathy complicated by tamponade: classic hemodynamic findings with a new disease. Circ J. 2010;122:1239–1241. 4. Eitel I, Lücke C, Grothoff M, et al. Inflammation in takotsubo cardiomyopathy: insights from cardiovascular magnetic resonance imaging. Eur Radiol. 2010;20:422–431. 5. Núñez Gil IJ, Andrés M, Almendro Delia M, et al. Characterization of tako-tsubo cardiomyopathy in Spain: results from the RETAKO national registry. Rev Esp Cardiol. 2015;68:505–512.


Clinical Chemistry and Laboratory Medicine | 2018

Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome

Alfredo Bardají; Gil Bonet; Anna Carrasquer; Maribel González-del Hoyo; Fernando Domínguez; Rafael Sánchez; Carme Boqué; Germán Cediel

Abstract Background: Detectable troponin below the 99th percentile may reflect an underlying cardiac abnormality which might entail prognostic consequences. This study aimed to investigate the prognosis of patients admitted to an emergency department (ED) with detectable troponin below the 99th percentile reference limit who did not present with an acute coronary syndrome (ACS). Methods: We analysed the clinical data of all consecutive patients admitted to the ED during the years 2012 and 2013 in whom cardiac troponin was requested by the attending clinician (cTnI Ultra Siemens, Advia Centaur). Patients with troponin below the 99th percentile of the reference population (40 ng/L) and who did not have a diagnosis of ACS were selected, and their mortality was evaluated in a 2-year follow-up. Results: A total of 2501 patients had a troponin level below the reference limit, with 43.9% of those showing detectable levels (>6 ng/L and <40 ng/L). Patients with detectable levels were elderly and had a higher prevalence of cardiovascular history and more comorbidities. The total mortality in the 2-year follow-up was 12.4% in patients with detectable troponin and 4.5% in patients with undetectable troponin (p<0.001). In the Cox multivariate regression analysis, the detectable troponin was an independent marker of mortality at 2 years (HR 1.62, 95% CI 1.07–2.45, p=0.021). Conclusions: Detectable troponin I below the 99th percentile is associated with higher mortality risk at 2-year follow-up in patients admitted to the ED who did not present with ACS.


Revista Espanola De Cardiologia | 2015

Troponina elevada en pacientes sin síndrome coronario agudo

Alfredo Bardají; Germán Cediel; Anna Carrasquer; Ramón de Castro; Rafael Sánchez; Carmen Boqué


Emergencias | 2018

Implicaciones diagnósticas y en el pronóstico de la elevación de troponina en ausencia de dolor torácico en pacientes atendidos en urgencias

Maribel González-del-Hoyo; Germán Cediel; Anna Carrasquer; G Bonet; L Consuegra-Sánchez; Alfredo Bardají


Emergencias | 2016

Pronóstico a un año de la elevación de troponina I en los pacientes dados de alta directamente desde un servicio de urgencias hospitalario

Germán Cediel; Anna Carrasquer; Rafael Sánchez; Carme Boqué; Maribel González-del-Hoyo; Alfredo Bardají


Revista Espanola De Cardiologia | 2018

Aceptación clínica de la definición universal del infarto de miocardio

Germán Cediel; Maribel González-del-Hoyo; Gil Bonet; Anna Carrasquer; Carme Boqué; Alfredo Bardají


European Heart Journal | 2017

P6434Early risk stratification of patients with positive troponin and without acute coronary syndrome

Germán Cediel; Anna Carrasquer; M. Gonzalez_Del_Hoyo; Rafael Sánchez; Carme Boqué; Alfredo Bardají


Emergencias | 2016

Implicaciones de una troponina elevada en pacientes dados de alta de un Servicio de Urgencias

Germán Cediel; Anna Carrasquer; Rafael Sánchez; Carme Boqué; Maribel González-del-Hoyo; Alfredo Bardaji Ruiz

Collaboration


Dive into the Anna Carrasquer's collaboration.

Top Co-Authors

Avatar

Germán Cediel

Rovira i Virgili University

View shared research outputs
Top Co-Authors

Avatar

Alfredo Bardají

Rovira i Virgili University

View shared research outputs
Top Co-Authors

Avatar

Carme Boqué

Rovira i Virgili University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge